- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03022097
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients (AVANT)
May 23, 2022 updated by: AstraZeneca
A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
1067
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Anhui, China, 230061
- Research Site
-
Baotou, China, 14010
- Research Site
-
Beijing, China
- Research Site
-
Beijing, China, 100050
- Research Site
-
Beijing, China, 100097
- Research Site
-
Beijing, China, CN-100083
- Research Site
-
Cangzhou, China, 61000
- Research Site
-
Changchun, China, 130021
- Research Site
-
Changsha, China, 430033
- Research Site
-
Changsha, China, 410005
- Research Site
-
Chengdu, China, 610072
- Research Site
-
Guangzhou, China, 510530
- Research Site
-
Haikou, China, 570311
- Research Site
-
Hangzhou, China, 310005
- Research Site
-
Hangzhou, China, 310003
- Research Site
-
Hangzhou, China, 310014
- Research Site
-
Hefei, China, 230001
- Research Site
-
Hefei, China, 230022
- Research Site
-
Hengyang, China, 50012
- Research Site
-
Hohhot, China, 010017
- Research Site
-
Liangyugang, China, 222002
- Research Site
-
Linhai, China, 317000
- Research Site
-
Nanchang, China, 330006
- Research Site
-
Nanjing, China, 210009
- Research Site
-
Qiqihar, China, 161005
- Research Site
-
Shanghai, China, 200433
- Research Site
-
Shanghai, China, 200030
- Research Site
-
Shanghai, China, 200062
- Research Site
-
Shanghai, China, 200090
- Research Site
-
Shanghai, China, 200040
- Research Site
-
Shanghai, China, 200240
- Research Site
-
Shanghai, China, 201200
- Research Site
-
Shanxi, China, 30001
- Research Site
-
Shengyang, China, 110004
- Research Site
-
Shenzhen, China, 518053
- Research Site
-
Shenzhen, China, 518020
- Research Site
-
Shijiazhuang, China, 050000
- Research Site
-
Taiyuan, China, 030001
- Research Site
-
Tianjin, China, 300052
- Research Site
-
Wenzhou, China, 325015
- Research Site
-
Wuxi, China, 214023
- Research Site
-
Xiamen, China, 361004
- Research Site
-
Xian, China, 710061
- Research Site
-
Xining, China, 810007
- Research Site
-
Yangzhou, China, 225000
- Research Site
-
Yanji, China, 133000
- Research Site
-
Yinchuan, China, 750004
- Research Site
-
Zhanjiang, China, 524001
- Research Site
-
-
-
-
-
Ahmedabad, India, 380060
- Research Site
-
Alappuzha, India, 688524
- Research Site
-
Ernakulam, India, 683577
- Research Site
-
Guntur, India, 522001
- Research Site
-
Jaipur, India, 302006
- Research Site
-
Kozhikode, India, 673008
- Research Site
-
Mysore, India, 57002
- Research Site
-
Nagpur, India, 440012
- Research Site
-
Nagpur, India, 440010
- Research Site
-
Nagpur, India, 440019
- Research Site
-
Pune, India, 411019
- Research Site
-
Pune, India, 411057
- Research Site
-
Pune, India, 440012
- Research Site
-
Vijayawada, India, 520 008
- Research Site
-
-
-
-
-
Caloocan City, Philippines, 1400
- Research Site
-
Iloilo City, Philippines, 5000
- Research Site
-
Manila, Philippines, 1000
- Research Site
-
Quezon City, Philippines, 1101
- Research Site
-
Quezon City, Philippines, 1100
- Research Site
-
Quezon City, Philippines, 1000
- Research Site
-
-
-
-
-
Keelung, Taiwan, 20448
- Research Site
-
Taichung, Taiwan, 40201
- Research Site
-
Taipei, Taiwan, 112
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 10000
- Research Site
-
Ho Chi Minh, Vietnam, 70000
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Research Site
-
Ho Chi Minh City, Vietnam, 70000
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 130 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1. Adult male or non-pregnant, non-lactating female patients aged ≥40
- 2. Patients with a diagnosis of COPD prior to Visit 1 (screening)
- 3. Patients with moderate to severe stable COPD (Stage II or Stage III) at Visit 1: post-bronchodilator FEV1 ≥30% and < 80% and post-bronchodilator FEV1/Forced vital capacity (FVC) < 70%
- 4. Current or former smokers with a smoking history of ≥ 10 pack-years
- 5. Patients able to perform repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1(screening)
- 6. Patients who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent
Exclusion Criteria:
- 1. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff) or patients employed by or relatives of the employees of the site or sponsor.
- 2. Previous enrolment or randomisation in the present study
- 3. History or current diagnosis of asthma
- 4. Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period
- 5. Patients hospitalized for COPD exacerbation (an emergency room visit for longer than 24 hours will be considered a hospitalization) within 3 months prior to screening and during the run-in period
- 6. Clinically significant respiratory conditions other than COPD
- 7. Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to screening
- 8. Use of long-term oxygen therapy (≥15 hours/day)
- 9. Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers
- 10. Clinically significant cardiovascular conditions
- 11. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension
- 12. Patients with QT corrected interval (QTc) using Fridericia formula (QTcF) (QTc=QT/ Duration in milliseconds between two R peaks of two consecutive QRS complexes (RR1/3) >470 msec as indicated in the centralised reading report assessed at Screening (Visit 1)
- 13. Patients with clinically significant abnormalities in the clinical laboratory tests, ECG parameters (other than QTcF) or in the physical examination at Visit 1 (screening)
- 14. Patients with abnormal liver function tests defined as Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), or total bilirubin ≥ 2.5 times upper limit of normal ranges at screening
- 15. Patient with known non-controlled history of infection with human immunodeficiency virus and/or active hepatitis
- 16. Patient with a history of hypersensitivity reaction to inhaled anticholinergic drugs, sympathomimetic amines, inhaled medication or any component thereof
- 17. Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy
- 18. History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer
- 19. Any other serious or uncontrolled physical or mental dysfunction
- 20. Patients with a history (within 2 years prior to Visit 1 (screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment
- 21. Patients unlikely to be cooperative or cannot comply with the study procedures
- 22. Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to screening
- 23. Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication
- 24. Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients
- 25. Any other conditions that, in the Investigator's opinion, might have indicated the patient to be unsuitable for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
|
EXPERIMENTAL: Experimental 1
Aclidinium bromide 400μg/Formoterol fumarate 12 μg
|
Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
|
EXPERIMENTAL: Experimental 2
Aclidinium bromide 400 μg
|
Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
|
ACTIVE_COMPARATOR: Comparator
Formoterol fumarate 12 μg
|
Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in 1-hour morning post-dose dose Forced expiratory volume in 1 second (FEV1)
Time Frame: Week 24
|
Change from baseline in 1-hour morning post-dose dose FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Aclidinium bromide at Week 24.
|
Week 24
|
Change from baseline in morning pre-dose (trough) FEV1
Time Frame: Week 24
|
Change from baseline in morning pre-dose (trough) FEV1 of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg compared to Formoterol fumarate at Week 24.
|
Week 24
|
Change from baseline in trough FEV1
Time Frame: Week 24
|
Change from baseline in trough FEV1 of Aclidinium bromide 400 μg compared to placebo at Week 24.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in peak FEV1
Time Frame: Week 24
|
Change from baseline in peak FEV1 of Aclidinium bromide 400 μg compared to placebo at week 24
|
Week 24
|
Improvements Transition Dyspnoea Index (TDI) focal score
Time Frame: Week 24
|
Improvements TDI focal score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24
|
Week 24
|
Change from baseline in St Georges Respiratory Questionnaire (SGRQ) total score
Time Frame: Week 24
|
Change from baseline in SGRQ total score of Aclidinium bromide 400 μg/Formoterol fumarate 12 μg and Aclidinium bromide 400μg compared to placebo at week 24
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 24, 2017
Primary Completion (ACTUAL)
April 14, 2022
Study Completion (ACTUAL)
April 14, 2022
Study Registration Dates
First Submitted
January 13, 2017
First Submitted That Met QC Criteria
January 13, 2017
First Posted (ESTIMATE)
January 16, 2017
Study Record Updates
Last Update Posted (ACTUAL)
May 24, 2022
Last Update Submitted That Met QC Criteria
May 23, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Anticonvulsants
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Bromides
- Formoterol Fumarate
Other Study ID Numbers
- D6570C00002
- M-AS464-30 (OTHER: Astrazenca)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on Aclidinium bromide/formoterol Fixed-Dose Combination
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Australia, Canada, New Zealand
-
University of Western Ontario, CanadaPfizerCompleted
-
International Union Against Tuberculosis and Lung...United States Agency for International Development (USAID)UnknownTuberculosisAlgeria, Bolivia, Colombia, Guinea, Mozambique, Nepal, Peru, Tanzania, Vietnam
-
University of DundeeAstraZeneca; NHS TaysideCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Russian Federation, Australia, Czech Republic, Poland
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Australia, Canada, New Zealand
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium, Germany
-
AstraZenecaRTI Health SolutionsCompletedPulmonary Disease, Chronic ObstructiveDenmark, Germany, United Kingdom
-
Rockefeller UniversityNational Institute on Drug Abuse (NIDA)Completed